Cantai Therapeutics has announced a seed financing co-led by Agent Capital and 82VS with participation from Tellus BioVentures.

Agent conceived the idea for Cantai's products and partnered with 82VS to further develop the concept. Agent's strong track record in financing companies in the autoimmune space paired with 82VS's company creation capabilities and deep bench of expert researchers is a perfect match to join forces to develop such therapies.